Morgan Stanley upgraded shares of Novo Nordisk A/S (NYSE:NVO) from an equal weight rating to an overweight rating in a research note released on Friday morning.

Other equities analysts also recently issued research reports about the company. BidaskClub raised Novo Nordisk A/S from a sell rating to a hold rating in a research report on Saturday, August 12th. BNP Paribas downgraded Novo Nordisk A/S from an outperform rating to a neutral rating in a research report on Monday, September 25th. Zacks Investment Research raised Novo Nordisk A/S from a hold rating to a buy rating and set a $55.00 price target for the company in a research report on Wednesday, September 13th. Finally, Bank of America raised Novo Nordisk A/S from an underperform rating to a neutral rating in a report on Wednesday, September 6th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $55.00.

Novo Nordisk A/S (NVO) traded up $0.22 during trading hours on Friday, reaching $51.99. The company’s stock had a trading volume of 1,550,000 shares, compared to its average volume of 1,560,000. Novo Nordisk A/S has a 52-week low of $32.83 and a 52-week high of $52.32. The firm has a market cap of $101,280.00, a P/E ratio of 22.61, a P/E/G ratio of 3.09 and a beta of 0.65.

In related news, insider Eric S. Sprott acquired 50,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The stock was bought at an average price of $8.34 per share, with a total value of $417,000.00. Corporate insiders own 0.07% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NVO. Keel Point LLC lifted its holdings in Novo Nordisk A/S by 0.4% during the 2nd quarter. Keel Point LLC now owns 6,748 shares of the company’s stock valued at $289,000 after purchasing an additional 24 shares during the last quarter. AlphaMark Advisors LLC lifted its holdings in Novo Nordisk A/S by 1.1% during the 2nd quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock valued at $113,000 after purchasing an additional 30 shares during the last quarter. Trillium Asset Management LLC lifted its holdings in Novo Nordisk A/S by 0.4% during the 2nd quarter. Trillium Asset Management LLC now owns 11,928 shares of the company’s stock valued at $512,000 after purchasing an additional 48 shares during the last quarter. Baldwin Investment Management LLC lifted its holdings in Novo Nordisk A/S by 1.4% during the 2nd quarter. Baldwin Investment Management LLC now owns 8,004 shares of the company’s stock valued at $343,000 after purchasing an additional 111 shares during the last quarter. Finally, Garrison Financial Corp lifted its holdings in Novo Nordisk A/S by 1.3% during the 2nd quarter. Garrison Financial Corp now owns 11,675 shares of the company’s stock valued at $501,000 after purchasing an additional 145 shares during the last quarter. 6.17% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Novo Nordisk A/S (NVO) Upgraded to “Overweight” by Morgan Stanley” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/12/02/novo-nordisk-as-nvo-upgraded-to-overweight-by-morgan-stanley.html.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.